A decade of tamoxifen reduces BCa recurrence

Article

Doubling the duration of adjuvant tamoxifen treatment in women estrogen receptor (ER)-positive breast cancer reduces risk of late recurrence and death compared with the current standard-of-care of 5 years' therapy. So say the results of a large international randomized trial presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium and simultaneously published in The Lancet.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Ciera Kirkpatrick, PhD, shows how TikTok is transforming cervical cancer awareness | Image Credit: linkedin.com.
Maria Gallo, PhD, discusses high attendance at crisis pregnancy centers | Image Credit: © x.com.
Eran Bornstein, MD, highlights early signs of preeclampsia clinicians need to know | Image Credit: northwell.edu.
Eran Bornstein, MD explains the need for first trimester preeclampsia screening | Image Credit: northwell.edu.
Veerle Bergink, MD, PhD, highlights familial links of postpartum psychosis | Image Credit: profiles.mountsinai.org.
Related Content
© 2025 MJH Life Sciences

All rights reserved.